Patents Assigned to Chinese Academy of Medical Science
  • Patent number: 11680086
    Abstract: The present application relates to a lipopeptide for potently inhibiting HIV, a derivative thereof, or a pharmaceutical composition thereof, and use thereof. The lipopeptide is the following a) or b): a) a lipopeptide formed by linking a polypeptide having an antiviral activity to a lipophilic compound linked to the carboxyl-terminus of the polypeptide; or b) a lipopeptide formed by linking a polypeptide having an antiviral activity to a terminal protecting group and a lipophilic compound linked to the carboxyl-terminus of the polypeptide, wherein the terminal protecting group is an amino-terminal protecting group and/or a carboxyl-terminal protecting group, the polypeptide has a sequence of 28 amino acid residues, corresponding to amino acids at positions of 127-154 of the sequence of gp41 from HIV-1 strain HXB2.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: June 20, 2023
    Assignees: Shanxi Kangbao Biological Product Co., Ltd., Institute of Pathogen Biology, Chinese Academy of Medical Sciences
    Inventors: Yuxian He, Huihui Chong, Yuanmei Zhu
  • Patent number: 11654141
    Abstract: The present invention provides use of berbamine dihydrochloride in preparation of an Ebola virus inhibitor. In the present invention, the primed glycoprotein of the Ebola virus (EBOV-GPcl) is taken as a target site, and an antiviral active compound with the capability of binding to the EBOV-GPcl, i.e., berbamine dihydrochloride, is obtained through structure-based virtual screening. Berbamine dihydrochloride can specifically inhibit the entry of an Ebola recombinant virus by binding to the target protein EBOV-GPcl, thereby achieving the effect of anti-Ebola virus infection. The half-maximum effect concentration (EC50) of berbamine dihydrochloride against EBOV is 0.49 ?M, which indicates that berbamine dihydrochloride has a strong inhibition effect on EBOV.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: May 23, 2023
    Assignee: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
    Inventors: Shan Cen, Quanjie Li, Dongrong Yi, Yi Shi, Han Wang, Jinming Zhou
  • Publication number: 20230134124
    Abstract: A method for evaluating an antiviral ability of a convalescent plasma by detecting an antibody against RBD of S protein, includes: preparing a convalescent plasma; detecting the antibody against RBD of S protein according to a principle of antigen-antibody specific binding; and evaluating the antiviral ability of the convalescent plasma according to a content of the antibody against RBD in detecting the antibody against RBD of S protein.
    Type: Application
    Filed: April 24, 2020
    Publication date: May 4, 2023
    Applicant: INSTITUTE OF BLOOD TRANSFUSION CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Zhong LIU, Ling LI, Jue WANG
  • Publication number: 20230132526
    Abstract: The present invention belongs to the technical field of protein and genetic engineering, and specifically discloses use of an erythropoietin human hepatocyte receptor B4 as a target in screening and preparing a biological formulation or medicament for increasing sensitivity to insulin. Also disclosed is use of an erythropoietin human hepatocyte receptor B4 in preparing an insulin-sensitized mouse model. On the basis of insulin signal regulation, a protein EphB4 capable of interacting with an insulin receptor (InsR) is found. The protein can interact with InsR, and insulin stimulation can promote the interaction between the two, which provides a basis for insulin resistance in the case of hyperinsulinaemia. Over-expression of EphB4 can promote degradation of InsR. Inhibition of EphB4 can enhance the sensitivity to insulin and improve insulin resistance.
    Type: Application
    Filed: December 30, 2020
    Publication date: May 4, 2023
    Applicant: Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Pingping LI, Xingfeng LIU, Bing CIU, Kai WANG, Jingwen CHEN, Shaocong HOU, Lijuan KONG, Qian JIANG, Chunxiao MA
  • Publication number: 20230099912
    Abstract: The present invention relates to a benzamide compound and a preparation method, use and pharmaceutical composition thereof. The benzamide compound represented by formula (I) is a STAT3 inhibitor, and can be used to prevent and/or treat a disease related to STAT3 activity, such as a tumor, autoimmune disease, renal disease, cardiovascular disease, inflammation, metabolic/endocrine dysfunction, and neurological disease.
    Type: Application
    Filed: October 27, 2022
    Publication date: March 30, 2023
    Applicant: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Heng XU, Xiaoguang CHEN, Songwen LIN, Ming JI, Nina XUE, Deyu WU, Jing JIN
  • Publication number: 20230087361
    Abstract: A dianthrone compound may be used in preparation of a medicament for prevention and/or treatment of myocardial ischemic diseases and related diseases thereof. The dianthrone compound includes trans-emodin dianthrone and/or cis-emodin dianthrone.
    Type: Application
    Filed: September 13, 2022
    Publication date: March 23, 2023
    Applicants: National Institutes for Food and Drug Control, Institute of Materia Medica Chinese Academy of Medical Sciences
    Inventors: Shuangcheng MA, Hua SUN, Feng WEI, Jianbo YANG, Ting OUYANG, Qi WANG, Zihan CHEN, Ying WANG, Yunfei SONG, Zhiwei CHEN, Huiyu GAO, Xueting WANG
  • Publication number: 20230071792
    Abstract: The present disclosure relates to primer and probe sets for pathogen detection of infection in a transplant patient, a kit and use thereof, and belongs to the technical field of molecular biology detection. There are 23 primer and probe sets that can be used to jointly detect 23 kinds of pathogens with a high infection rate and a high lethality rate after transplantation, including an adenovirus type B; and two ends of a corresponding sequence of each probe have correspondingly a fluorophore and a quencher group, respectively. The present disclosure further provides a real-time fluorescence quantitative PCR kit for pathogen detection of infection in a transplant patient, including the primer and probe sets, a pathogen plasmid standard, a fluorescence quantitative PCR reaction solution, and sterile deionized water, which can simultaneously detect 23 pathogens infected by the transplant patient.
    Type: Application
    Filed: July 14, 2022
    Publication date: March 9, 2023
    Applicant: Institute of Blood Transfusion, Chinese Academy of Medical Sciences
    Inventors: Miao HE, Shan LIANG
  • Publication number: 20230002343
    Abstract: The invention relates to the field of pharmaceutical chemistry, and it particularly relates to a left-handed bicyclic morpholine and a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition and use thereof in the preparation of medicaments for preventing and/or treating liver diseases and the like.
    Type: Application
    Filed: September 15, 2020
    Publication date: January 5, 2023
    Applicants: Institute of Materia Medica, Chinese Academy of Medical Sciences, Changchun Intellicrown Pharmaceutical Co., Ltd.
    Inventors: Song WU, Hua SUN, Jinlan ZHANG, Wenxuan ZHANG, Zhe WANG, Qingyun YANG, Lin JIANG, Zihan CHEN, Jing SHEN, Jie ZHANG, Chi ZHANG, Zunsheng HAN, Tong QIN, Yuanyuan ZHANG
  • Patent number: 11541250
    Abstract: A method for planning a scan path for intraoperative radiation therapy may comprise acquiring a plurality of images of a region of interest through an auxiliary scanning component, establishing a 3D model of the region of interest based on the plurality of images of the region of interest, determining a radiation therapy volume based on the 3D model of the region of interest, and planning a scan path for a radiation therapy component to scan the radiation therapy volume.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: January 3, 2023
    Assignee: Cancer Hospital, Chinese Academy of Medical Sciences
    Inventors: Jianrong Dai, Pan Ma, Chuanmeng Niu, Minghui Li
  • Patent number: 11534443
    Abstract: The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and/or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders or neurological diseases.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: December 27, 2022
    Assignee: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Heng Xu, Xiaoguang Chen, Songwen Lin, Ming Ji, Jing Jin, Deyu Wu, Chunyang Wang, Yuanhao Lv
  • Patent number: 11518744
    Abstract: The present invention relates to a benzamide compound and a preparation method, use and pharmaceutical composition thereof. The benzamide compound represented by formula (I) is a STAT3 inhibitor, and can be used to prevent and/or treat a disease related to STAT3 activity, such as a tumor, autoimmune disease, renal disease, cardiovascular disease, inflammation, metabolic/endocrine dysfunction, and neurological disease.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: December 6, 2022
    Assignee: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Heng Xu, Xiaoguang Chen, Songwen Lin, Ming Ji, Nina Xue, Deyu Wu, Jing Jin
  • Publication number: 20220380381
    Abstract: The present invention belongs to the field of medical technology and relates to a class of functional small molecules targeting proteolysis pathways, a preparation and an application thereof. Specifically, the present invention relates to functional small molecules represented by formula (M) and pharmaceutically acceptable salts thereof, as well as the application of said compounds and pharmaceutical compositions thereof in the preparation of tumor-treating drugs. The functional small molecules are obtained by means of linking a compound containing a peroxide bridge linkage and a substrate of an E3 ubiquitin ligase complex. The related functional molecules can promiscuously target and bind to multiple proteins comprising functional proteins in the proteolysis pathway and have anti-tumor biological activity.
    Type: Application
    Filed: September 9, 2020
    Publication date: December 1, 2022
    Applicant: Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Chongjing Zhang, Fujia Wang, Zi Ye, Wanqi Yang, Ke Li
  • Publication number: 20220330889
    Abstract: Disclosed is an artificial intelligence infrared thermal imaging bra system with breast disease detecting function. The system includes a side support, two chest support layers and two shoulder straps; the two shoulder straps are fixed at both ends of the side support, and the two chest support layers are symmetrically fixed between the two shoulder straps at the top of the side support; the two chest support layers are internally provided with sliding mechanisms that are adjustable according to different chests of users; a rotating mechanism for driving the sliding mechanisms to move is arranged between the two chest support layers at the top of the side support, and the rotating mechanism and the sliding mechanisms are in transmission connection; one end of the side support is fixed with a sub-buckle, and the other end of the side support is provided with a stretching mechanism.
    Type: Application
    Filed: July 6, 2022
    Publication date: October 20, 2022
    Applicant: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Inventors: Xuefei WANG, Guanyu ZHOU, Qiang SUN, Jidong ZHAI, Likun HUNAG, Yidong ZHOU, Guochao ZHANG, Feng MAO, Yan LIN, Songjie SHEN, Xiaohui ZHANG, Xuejing WANG
  • Patent number: 11471476
    Abstract: Provided are microRNA from a rhodiola root and uses thereof in the prevention and/or the treatment of a fibroplasia medical sign and/or syndrome.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: October 18, 2022
    Assignee: INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Chengyu Jiang, Jianchao Du, Zhu Liang, Jiantao Xu, Yan Zhao
  • Publication number: 20220267734
    Abstract: Disclosed are a heterogeneous stem cell population, a preparation method therefor, and the use thereof. Specifically, disclosed is a heterogeneous stem cell population, characterized in that stem cells in the heterogeneous stem cell population express stemness genes MYC, KLF4, GMNN, SOX2 and NANOG, and in the heterogeneous stem cell population, the ratio of stem cells expressing CD146 is 1%-50%.
    Type: Application
    Filed: June 18, 2020
    Publication date: August 25, 2022
    Applicant: INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventor: Chunhua ZHAO
  • Publication number: 20220257710
    Abstract: Provided are anti-infection effects of a heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) and use thereof. In particular, provided are use of hnRNPA2B1, a nucleic acid molecule encoding the protein, and an accelerator thereof or an inhibitor thereof in the preparation of a product for preventing and/or treating infectious diseases and/or diseases and/or conditions associated with infection, and a corresponding pharmaceutical composition or kit thereof. The present disclosure can be used for preventing and inhibiting infections (such as virus infections) and diagnosing and treating autoimmune diseases related to self-nucleic acids, and has wide application prospects.
    Type: Application
    Filed: July 17, 2019
    Publication date: August 18, 2022
    Applicant: INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Xuetao CAO, Lei WANG, Mingyue WEN
  • Publication number: 20220241407
    Abstract: The present disclosure provides combined adjuvants nanoparticles prepared by self-assembly with amphiphilic monomer molecules as the building blocks, wherein the amphiphilic monomer molecules are generated from the reaction between hydrophobic adjuvants molecules and hydrophilic adjuvants molecules.
    Type: Application
    Filed: June 17, 2020
    Publication date: August 4, 2022
    Applicant: INSTITUTE OF BIOMEDICAL ENGINEERING, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: LANXIA LIU, DAN LIU, JIALE LIU, XIGANG LENG
  • Patent number: 11398294
    Abstract: A method for controlling the quality of traditional Chinese patent medicines is based on metagenomics. The method includes extracting genomic DNA of a sample of the traditional Chinese patent medicine, constructing a library of the genomic DNA based on a high-throughput sequencing platform, and performing metagenomic sequencing. The data obtained from the metagenomic sequencing is processed to obtain the ITS2 sequence of the traditional Chinese patent medicine sample A BLAST alignment is performed on the ITS2 sequence in the DNA Barcoding System for Identifying Herbal Medicine, to obtain species identification results. The obtained identification results are compared with the labeled species of the traditional Chinese patent medicine to obtain a conclusion about the quality of the traditional Chinese patent medicine sample.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: July 26, 2022
    Assignee: Institute of Medicinal Plant Development, Chinese Academy of Medical Science
    Inventors: Jingyuan Song, Tianyi Xin, Zhichao Xu, Jing Jia
  • Patent number: 11332477
    Abstract: The present invention discloses a nitrogen-containing heterocyclic substituted benzoxazine oxazolidinone compound, a preparation method and use thereof in the manufacture of a medicament for treating and/or preventing infectious diseases caused by Mycobacterium tuberculosis. Specifically, the present invention relates to a compound represented by formula (I) and stereoisomer thereof, pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compounds of the present invention, use thereof, a method for preparing the compound, in which X1, X2, R1 and R2 are described in the specification.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: May 17, 2022
    Assignee: Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Haihong Huang, Dongfeng Zhang, Hongyi Zhao
  • Publication number: 20220143074
    Abstract: The present invention relates to the technical field of medicine, in particular to a chondroitin sulfate polysaccharide, and a semi-synthetic preparation method therefor and the use thereof. A metal salt of the chondroitin sulfate polysaccharide provided by the present invention has an anti-inflammatory effect, and can be used for preparing a drug against inflammatory diseases. In particular, the metal salt of the chondroitin sulfate polysaccharide provided by the present invention has anti-inflammatory and bone-protecting effects, and can be used for preparing a drug against rheumatoid arthritis and for preparing a drug against osteoarthritis. The present invention provides a method for preparing the metal salt of the chondroitin sulfate polysaccharide, and the metal salt of the chondroitin sulfate polysaccharide with different degrees of sulfation can be obtained by semi-synthetic means in the present invention. The method is simple to operate and suitable for large-scale production.
    Type: Application
    Filed: March 5, 2020
    Publication date: May 12, 2022
    Applicant: Institute of Materia Medica, Chinese Academy of Medical Sciences
    Inventors: Zhehui ZHAO, Pingsheng LEI, Lianqiu WU, Shuang YANG, Wenjie WANG, Haijing ZHANG, Xiang LI